Innovative Health Technologies Limited v. Crawford

CourtDistrict Court, D. Arizona
DecidedJuly 29, 2020
Docket2:18-cv-03372
StatusUnknown

This text of Innovative Health Technologies Limited v. Crawford (Innovative Health Technologies Limited v. Crawford) is published on Counsel Stack Legal Research, covering District Court, D. Arizona primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Innovative Health Technologies Limited v. Crawford, (D. Ariz. 2020).

Opinion

1 WO 2 3 4 5 6 IN THE UNITED STATES DISTRICT COURT 7 FOR THE DISTRICT OF ARIZONA

9 Innovative Health Technologies, No. CV-18-03372-PHX-ROS

10 Plaintiff, ORDER AND FINAL JUDGMENT

11 v.

12 Rustam Urmeev,

13 Defendant. 14 15 Plaintiff Innovative Health Technologies (“IHT”) seeks default judgment against 16 Defendant Rustam Urmeev. (Doc. 72). While IHT is entitled to default judgment, it is not 17 entitled to the full amount of monetary damages it seeks nor is it entitled to the full scope 18 of injunctive relief it requests. Thus, the motion for default judgment will be granted in 19 part. 20 BACKGROUND 21 “The general rule of law is that upon default the factual allegations of the complaint, 22 except those relating to the amount of damages, will be taken as true.” TeleVideo Sys., Inc. 23 v. Heidenthal, 826 F.2d 915, 917-18 (9th Cir. 1987). The second amended complaint sets 24 forth the following facts. (Doc. 38). “IHT is a market leader in innovative medical devices 25 for the consuming public.” (Doc. 38 at 5). After years of research, IHT developed its 26 “AVEOtsd apparatus” to treat snoring and sleep apnea. That apparatus is “a one-piece 27 tongue stabilizing device formed of a resiliently flexible material and comprises a body 28 having a hollow interior within which the end of a user’s tongue fits and is held by negative 1 pressure.” (Doc. 38 at 5). IHT obtained a patent covering that apparatus (“the ‘506 2 Patent”) and began selling the apparatus throughout the United States and internationally. 3 IHT advertises the apparatus on a nationwide and worldwide basis. 4 Sometime prior to 2017, Urmeev and his partners established a business known as 5 “ZenSleep.” As early as January 2017, Urmeev and his partners manufactured and sold a 6 variety of “snoring solutions” through ZenSleep. One of those “snoring solutions” was an 7 apparatus known as the “ZenGuard.” (Doc. 38 at 7). The ZenGuard reads on all the claims 8 of IHT’s patent. In fact, it appears to be a simple copy of the AVEOtsd apparatus. In 9 marketing the ZenGuard, Urmeev claimed he invented the ZenGuard and that there was 10 “nothing like [it] on the market.” (Doc. 38 at 7). And on the ZenSleep website, Urmeev 11 claimed ZenSleep was an “FDA Approved Facility” and that the facility had been featured 12 in publications such as Forbes and WebMD. (Doc. 38 at 8). All of these representations 13 by Urmeev were false. In addition, the ZenSleep website contained an instructional video 14 allegedly explaining how to use the ZenGuard. That video, however, “actually shows 15 IHT’s AVEOtsd devoice, and not the infringing ZenGuard product.” (Doc. 38 at 8-9). 16 Using a video showing IHT’s product to advertise the ZenGuard establishes Urmeev was 17 aware of IHT’s product and was consciously attempting to capitalize on that product’s 18 success. 19 IHT learned of Urmeev’s sale of the infringing apparatus and repeatedly informed 20 him that he was infringing the ‘506 Patent and engaged in false advertising. Urmeev 21 ignored those communications and continued to sell the infringing apparatus. Thus, 22 Urmeev had “actual knowledge and notice of IHT’s ownership of the ‘506 Patent” but 23 continued his infringing activities. (Doc. 38 at 10). 24 In October 2018, IHT filed the present suit against Urmeev’s business partners. 25 (Doc. 1). Later, IHT added Urmeev as a defendant. (Doc. 38). IHT alleged two claims 26 against Urmeev and his partners: 1) patent infringement; and 2) false advertising/unfair 27 competition under federal law. (Doc. 38 at 10-11). IHT alleged Urmeev’s conduct was 28 “willful, wanton, and deliberate” such that any damages for patent infringement or false 1 advertising should be trebled. (Doc. 38 at 13-14). 2 Urmeev avoided service but was eventually served through mail, email, publication, 3 and his attorneys for other matters. (Doc. 60). Urmeev never appeared and his default was 4 entered.1 (Doc. 73). As for his partners, they were served and they filed an answer. The 5 partners produced discovery indicating Urmeev and his partners had total profits in 2017 6 of $1,558,568 and total profits in 2018 of $406,735.89. No documentation was produced 7 regarding 2016 or 2019. Thus, Urmeev’s total profits during the relevant time of 2016 8 through 2019 were $1,965,303.89. That figure is established by documentation produced 9 by Urmeev’s own business partners and there is no reason to doubt the figure’s accuracy. 10 IHT and Urmeev’s business partners eventually settled, leaving Urmeev the sole 11 defendant.2 12 ANALYSIS 13 There are seven factors the Court must consider when determining whether to enter 14 default judgment: “(1) the possibility of prejudice to the plaintiff, (2) the merits of 15 plaintiff’s substantive claim, (3) the sufficiency of the complaint, (4) the sum of money at 16 stake in the action; (5) the possibility of a dispute concerning material facts; (6) whether 17 the default was due to excusable neglect, and (7) the strong policy underlying the Federal 18 Rules of Civil Procedure favoring decisions on the merits.” Eitel v. McCool, 782 F.2d 19 1470, 1471-72 (9th Cir. 1986). These factors support entry of default judgment. 20 First, given Urmeev’s refusal to appear or participate in this litigation, IHT has no 21 other means of obtaining redress for Urmeev’s behavior. Thus, absent a default judgment 22 IHT will suffer severe prejudice. 23 The second and third factors can be analyzed together as they involve the adequacy 24 of the complaint and the strength of IHT’s claims. The second amended complaint

25 1 In connection with the entry of default, IHT complied with the Servicemembers Civil Relief Act by submitting an affidavit stating “Defendant Urmeev is not in the military or 26 in military service.” (Doc. 71-1 at 2). 2 The docket also lists “Ecommerce Incubator LLC” as a defendant but that entity appears 27 to no longer exist and IHT does not request judgment be entered against it. Simiarly, the docket lists Urmeev’s spouse, “Jane Doe Urmeev,” as a party. There is no indication that 28 Urmeev is married or that his spouse was served. Therefore, all claims against Ecommerce Incubator LLC and Jane Doe Urmeev will be dismissed. 1 adequately alleges Urmeev has repeatedly and intentionally made false statements in 2 advertising the ZenGuard product. Those statements had a tendency to deceive a 3 substantial portion of the public and influence purchasing decisions. And IHT was injured 4 because Urmeev diverted sales from IHT. The second amended complaint also adequately 5 alleges that Urmeev has manufactured and sold products that infringe IHT’s patent. 6 Accordingly, IHT’s complaint and substantive claims are strong. 7 The fourth factor requires the Court consider the amount of money at stake. There 8 is a substantial sum at stake. Urmeev has enjoyed close to two million dollars in profits by 9 false advertising and infringing IHT’s patent. That sum of money, together with Urmeev’s 10 refusal to participate in this litigation, supports granting IHT default judgment, the only 11 form of relief available. 12 The fifth factor requires the Court evaluate whether there might be disputes 13 regarding material facts. There is no basis in the record for concluding disputes are 14 possible. Given Urmeev’s blatantly false advertising and his clear infringement of IHT’s 15 patent, it is unlikely that Urmeev’s involvement in this suit would have created any genuine 16 disputes regarding the material facts. 17 The sixth factor requires the Court assess why Urmeev failed to appear. There is no 18 indication that Urmeev’s failure to appear is because of excusable neglect. 19 The seventh and final factor requires the Court address the strong preference for 20 resolution of cases on their merits.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
Innovative Health Technologies Limited v. Crawford, Counsel Stack Legal Research, https://law.counselstack.com/opinion/innovative-health-technologies-limited-v-crawford-azd-2020.